NeuBase Therapeutics, Inc. - FORM 10-K - EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - December 14, 2015

Attached files

file filename
EX-23 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - NeuBase Therapeutics, Inc.ex23.htm
EX-14 - CODE OF ETHICS - NeuBase Therapeutics, Inc.ex14.htm
EX-21 - LIST OF SUBSIDIARIES OF OHR PHARMACEUTICAL. INC. - NeuBase Therapeutics, Inc.ex21.htm
EX-31.2 - CHIEF FINANCIAL OFFICER AND PRINCIPAL ACCOUNTING OFFICER - NeuBase Therapeutics, Inc.ex31-2.htm
EX-32.2 - CHIEF FINANCIAL OFFICER AND PRINCIPAL ACCOUNTING OFFICER - NeuBase Therapeutics, Inc.ex32-2.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - NeuBase Therapeutics, Inc.ex31-1.htm
EX-10.8(B) - AMENDMENT TO 2014 STOCK INCENTIVE PLAN - NeuBase Therapeutics, Inc.ex10-8b.htm
EX-10.2(E) - LOCK-UP AGREEMENT - NeuBase Therapeutics, Inc.ex10-2e.htm
EX-10.2(D) - RESTRICTED STOCK AGREEMENT - NeuBase Therapeutics, Inc.ex10-2d.htm
EX-10.2(C) - CONSULTING AGREEMENT AND RELEASE - NeuBase Therapeutics, Inc.ex10-2c.htm
EX-10.3(C) - PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT - NeuBase Therapeutics, Inc.ex10-3c.htm
10-K - ANNUAL REPORT - NeuBase Therapeutics, Inc.ohrp-10k_093015.htm
EX-10.2(F) - PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT - NeuBase Therapeutics, Inc.ex10-2f.htm

 

Ohr Pharmaceutical, Inc. 10-K

 

Exhibit 32.1

 

Certification of Chief Executive Officer
Pursuant to 18 U.S.C Section 1350,
As Adopted Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002

  

Not Filed Pursuant to the Securities Exchange Act of 1934

 

In connection with the Annual Report of Ohr Pharmaceutical, Inc. (the “Company”) on Form 10-K for the fiscal year ended September 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jason Slakter, Chief Executive Officer, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: December 14, 2015

 

/s/ Jason Slakter  
Name: Jason Slakter  
Title: Chief Executive Officer  

 

 

 

 

NeuBase Therapeutics, Inc. Reports